Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 238

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 1
Chunk 238
---
22,749)Segment income (loss) (3)$26,927 $17,594 $(50,451)$20,259 (1)The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.(2)Other segment items includes the net of: bad debt expense (Note 6), interest income, interest expense, sublease income (Note 5), loss on debt extinguishment (Note 7), other expenses, and provision for income taxes, as presented on the face of our condensed consolidated statements of operations.(3)Net income (loss) is our reported measure of segment profit or loss.

9. Revenue Recognition 

Disaggregation of RevenuesThe following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands): Three Months EndedSeptember 30, 2025Three Months EndedSeptember 30, 2024 U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, net     HEPLISAV-B$89,954 $- $89,954 $79,345 $- $79,345 Total product revenue, net89,954 - 89,954 79,345 - 79,345 Other revenue4,739 183 4,922 1,263 22 1,285 Total revenues$94,693 $183 $94,876 $80,608 $22 $80,630 Nine Months EndedSeptember 30, 2025Nine Months EndedSeptember 30, 2024U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, netHEPLISAV-B$245,163 $1,622 $246,785 $195,030 $2,347 $197,377 Total product revenue, net245,163 1,622 246,785 195,030 2,347 197,377 Other revenue10,903 794 11,697 7,663 174 7,837 Total revenues$256,066 $2,416 $258,482 $202,693 $2,521 $205,214 Revenues from Major Customers and Collaboration PartnersHEPLISAV-B product sales in the U.S. are to certain wholesalers and specialty distributors whose customers include integrated delivery networks, retail pharmacies